Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer

Neoplasms, Breast Clinical Trial

Official title:

A Phase II, Open-Label, Randomized, Multicenter Trial of GW786034 (Pazopanib) in Combination With Lapatinib (GW572016) Compared to Lapatinib Alone as First Line Therapy in Subjects With Advanced or Metastatic Breast Cancer With ErbB2 Fluorescence In Situ Hybridization (FISH) Positive Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00347919
• Other study ID #: VEG20007
• Status: Completed
• Phase: Phase 2
• First received: June 30, 2006
• Last updated: January 28, 2016
• Start date: July 2006
• Est. completion date: March 2015

Study information

• Verified date: January 2016
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This study is being conducted to compare the efficacy and safety of pazopanib in combination with lapatinib with that of lapatinib alone in subjects with locally advanced or metastatic breast cancer whose tumors overexpress the ErbB2 protein.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 189
• Est. completion date: March 2015
• Est. primary completion date: August 2008
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 21 Years and older

Eligibility

Inclusion Criteria:

• A subject will be eligible for inclusion in this study only if all of the following criteria apply:

• Women = 18 years of age with a life expectancy of = 12 weeks.

• Note: National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) and Alzheimer's Disease and Related Disorders Association (ADRDA).)

• Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1.

• Histologically confirmed invasive breast cancer with incurable stage IIIb, stage IIIc with T4 lesion, or stage IV disease at primary diagnosis or at relapse after curative-intent surgery.

• No prior chemotherapy, immunotherapy, biologic therapy or anti-ErbB1/ErbB2 therapy for metastatic or recurrent disease (other than neoadjuvant or adjuvant therapy). Prior hormonal therapy (e.g., tamoxifen, raloxifen or an aromatase inhibitor) for advanced or metastatic disease is permitted provided at least 2 weeks have elapsed between the completion of the prior therapy and start of study drugs.

• Note: Subjects must have documented progressive disease (PD) or be intolerant to hormonal therapy. This must be documented in the source documentation.

• Prior neoadjuvant therapy and/or adjuvant therapy is permitted.

• Note:

• (a) Subjects who have received both neoadjuvant and adjuvant therapies must have at least 6 months between completion of the chemotherapy-component of adjuvant therapy and start of study drug(s)

• (b) Subjects who have received only adjuvant therapy must have at least 6 months between completion of the chemotherapy-component of adjuvant therapy and start of study drug(s)

• (c) Subjects who have received only neoadjuvant therapy must have at least 6 months between completion of neoadjuvant therapy and start of study drug(s)

• (d) Subjects who have received trastuzumab or hormonal agents as all or part of adjuvant therapy are eligible provided: (1) 2 weeks have elapsed since last dose (2) 6 months have elapsed between the start of trastuzumab or hormonal therapy and start of study drugs.

• Radiotherapy prior to initiation of randomized therapy to a limited area (e.g., palliative treatment for painful disease) other than the sole site of measurable and assessable disease is allowed however, subjects must have completed treatment at least 4 weeks prior to starting study drugs, and must have recovered from all treatment-related toxicities prior to starting pazopanib and/or lapatinib.

• Documented amplification of ErbB2 by Fluorescence In Situ Hybridization (FISH) in either the primary or metastatic tumor tissue. Archived tumor tissue must be provided for ErbB2 FISH testing by the central laboratory, which will be used to determine eligibility.

• Note: Subjects that have documented ErbB2 amplification based on prior FISH testing or documented ErbB2 overexpression based on prior immunohistochemistry (IHC) with a value of 3+ are eligible, however, archived tumor tissue must be provided for confirmation by the central laboratory. If the results from prior testing are not confirmed by the central laboratory, then the subject can continue to receive study drug(s) at the discretion of the investigator, but will be excluded from the statistical analysis.

• Archived tumor tissue (paraffin-embedded) must be available to correlate tumor response with intra-tumoral genetic changes as well as expression levels of relevant biomarkers. Results of biomarkers will not be used to determine subject eligibility for the study.

• Ability to swallow and retain oral medication.

• Disease must be measurable according to Response Evaluation Criteria in Solid Tumors (RECIST).

• Subjects must have chosen treatment with lapatinib and/or pazopanib as initial treatment over other initial treatments (such as cytotoxic chemotherapy regimens or trastuzumab as a single agent) for locally advanced or metastatic disease.

• Adequate organ function as defined below:

• System (Laboratory Values)

• Hematologic:Absolute neutrophil count (ANC) (=1.5 X 109/L) Platelets (=100 X 109/L)

• Hepatic:Albumin(=2.5 g/dL)Serum bilirubin(=1.5 X upper limit of normal (ULN) unless due to Gilbert's syndrome) aspartate aminotransferase (AST) and alanine aminotransferase (ALT) (=2.0 X ULN)

• Renal:Calculated creatinine clearance1 (=50 mL/min) Urine Protein2

• (Negative, trace or +1 by dipstick urinalysis or <1.0 gram determined by 24 hour urine protein analysis).

• A patient should first be screened with dipstick urinalysis. If urine protein by dipstick analysis is=2+, then a 24-hour urine protein must be assessed and 24 hour urine protein must be <1 g protein to be eligible.

• Cardiac ejection fraction within the institutional range of normal as measured by echocardiogram. Multigated acquisition (MUGA) scans will be accepted in cases where an echocardiogram cannot be performed or is inconclusive or where MUGA scans are the accepted standard. Subjects with known history of uncontrolled or symptomatic angina, arrhythmias, or congestive heart failure are not eligible.

• A female is eligible to enter and participate in this study if she is of:

• Non-childbearing potential (i.e., physiologically incapable of becoming pregnant), including any female who has had:

• A hysterectomy

• A bilateral oophorectomy (ovariectomy)

• A bilateral tubal ligation

• Is post-menopausal (total cessation of menses for =1 year)

• Childbearing potential, has a negative serum pregnancy test within 2 weeks of the first dose of study medication, and agrees to use adequate contraception during study participation and for a minimum of 2 menstrual cycles after the last dose of study medication. GSK acceptable contraceptive methods, when used consistently and in accordance with both the product label and the instructions of the physician, are as follows:

• An intrauterine device with a documented failure rate of less than 1% per year.

• Vasectomized partner who is sterile prior to the female subject's entry and is the sole sexual partner for that female.

• Complete abstinence from sexual intercourse for 14 days before exposure to investigation product, through the clinical trial, and for at least 2 menstrual cycles after the last dose of investigational product.

• Double-barrier contraception (condom with spermicidal jelly, foam suppository, or film; diaphragm with spermicide; or male condom and diaphragm with spermicide).

• Oral contraceptives are not reliable due to the potential drug-drug interactions.

• Subjects must complete all screening assessments as outlined in the protocol.

• Subjects must provide written informed consent prior to performance of any study-specific procedures or assessments and are willing to comply with treatment and follow-up.

Exclusion Criteria:

• A subject will not be eligible for inclusion in this study if any of the following criteria apply:

• Subjects with bilateral breast cancer or bone metastases as the only disease site.

• Patients with high disease burden defined as >30% replacement of hepatic parenchyma with metastases, symptomatic pulmonary metastases (e.g., clinically significant dyspnea, cough, or chest pain attributable to pulmonary metastases), or >3 visceral organs with tumor involvement.

• History of other malignancy. Subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible.

• Sarcoma histology.

• Concurrent disease or condition that would make the subject inappropriate for study participation including (1) any unresolved or unstable, serious toxicity from prior administration of another investigational drug, (2) any serious medical disorder that would interfere with the subject's safety, obtaining informed consent or compliance to the study.

• History or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis, except for individuals who have previously treated CNS metastases, are asymptomatic, and have had no requirement for steroids or antiseizure medication for ³ 2 months prior to study enrollment. Routine screening with CNS imaging studies (computed tomography [CT] or magnetic resonance imaging [MRI]) is required only if clinically indicated or if the subject has a history of CNS metastases.

• Malabsorption Syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel.

• Active peptic ulcer disease, inflammatory bowel disease, or other gastrointestinal condition increasing the risk of perforation; history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 4 weeks prior to beginning therapy.

• Presence of uncontrolled infection.

• Concurrent cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, hormonal therapy, and tumor embolization).

• Concurrent treatment with an investigational agent or participation in another clinical trial.

• Use of an investigational anti-cancer drug within 30 days or 5 half-lives, whichever is longer, preceding the first dose of pazopanib and/or lapatinib.

• Prior use of an investigational or licensed drug that targets either vascular endothelial growth factor (VEGF) or VEGF receptors, or ErbB2 (except for trastuzumab when used in the neo-adjuvant/adjuvant setting).

• Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib or lapatinib.

• Has taken/is taking prohibited medications, Lapatinib-related, orPazopanib-related.

• Corrected QT interval (QTc) prolongation defined as QTc interval > 480 msecs.

• History of any one of the following cardiac conditions within the past 6 months:

• Cardiac angioplasty or stenting

• Myocardial infarction

• Unstable angina

• History of cerebrovascular accident within the past 6 months.

• Poorly controlled hypertension (systolic blood pressure (SBP) of =140mmHg, or diastolic blood pressure (DBP) of =90mmHg).

• Note: Initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry. The blood pressure (BP) must be re-assessed on two occasions that are separated by a minimum of 24 hours. The mean SBP/DBP values from both BP assessments must be < 140/90mmHg in order for a subject to be eligible for the study.

• Presence of any non-healing wound, fracture, or ulcer, or the presence of symptomatic peripheral vascular disease.

• Evidence of bleeding diathesis or coagulopathy.

• Major surgical procedure, open biopsy, or significant traumatic injury within 4 weeks prior to beginning therapy, or anticipation of the need for a major surgical procedure during the course of the study; minor surgical procedures such as fine needle aspiration or core biopsy within 1 week prior to beginning therapy are also excluded.

• Pregnant or lactating female.

• Has Class III or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system.

• History of untreated deep venous thrombosis (DVT) within the past 6 months (e.g. calf vein thrombosis).

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Breast Neoplasms
• Neoplasms, Breast

Intervention

Drug:
• pazopanib (GW786034) 400 mg
400 mg administered orally once daily
• lapatinib (GW572016) 1500 mg
1500 mg administered orally once daily.
• lapatinib (GW572016) 1000 mg
1000 mg administered orally once daily
• pazopanib (GW786034) 800 mg
800 mg administered orally once daily

Locations

Country	Name	City	State
Canada	GSK Investigational Site	Edmonton	Alberta
Canada	GSK Investigational Site	Halifax	Nova Scotia
Canada	GSK Investigational Site	Weston	Ontario
France	GSK Investigational Site	Besançon
France	GSK Investigational Site	Hyeres
France	GSK Investigational Site	Lille Cedex
France	GSK Investigational Site	Lyon cedex 03
France	GSK Investigational Site	Marseille Cedex BP 156
France	GSK Investigational Site	Paris Cedex 5
France	GSK Investigational Site	Strasbourg
Hungary	GSK Investigational Site	Budapest
Hungary	GSK Investigational Site	Budapest
Hungary	GSK Investigational Site	Gyor
India	GSK Investigational Site	Bangalore
India	GSK Investigational Site	Delhi
India	GSK Investigational Site	Jaipur
India	GSK Investigational Site	Mumbai
India	GSK Investigational Site	Pune
India	GSK Investigational Site	Pune
India	GSK Investigational Site	Trivandrum
Israel	GSK Investigational Site	Haifa
Israel	GSK Investigational Site	Jerusalem
Israel	GSK Investigational Site	Petach Tikva
Israel	GSK Investigational Site	Ramat Gan
Israel	GSK Investigational Site	Rehovot
Israel	GSK Investigational Site	Tel Aviv
Korea, Republic of	GSK Investigational Site	Incheon
Korea, Republic of	GSK Investigational Site	seodaemun-gu, Seoul
Korea, Republic of	GSK Investigational Site	songpa-gu, Seoul
Korea, Republic of	GSK Investigational Site	Suwon, Kyonggi-do
Malaysia	GSK Investigational Site	Bandar Tun Razak, Cheras
Malaysia	GSK Investigational Site	Petaling Jaya
Mexico	GSK Investigational Site	Merida	Yucatán
Mexico	GSK Investigational Site	Mexico City
Pakistan	GSK Investigational Site	Islamabad
Pakistan	GSK Investigational Site	Karachi
Pakistan	GSK Investigational Site	Lahore
Pakistan	GSK Investigational Site	Lahore
Pakistan	GSK Investigational Site	Multan
Peru	GSK Investigational Site	Callao
Peru	GSK Investigational Site	Lima
Peru	GSK Investigational Site	Lima
Poland	GSK Investigational Site	Elblag
Poland	GSK Investigational Site	Kielce
Poland	GSK Investigational Site	Kraków
Poland	GSK Investigational Site	Olsztyn
Poland	GSK Investigational Site	Olsztyn
Poland	GSK Investigational Site	Warszawa
Russian Federation	GSK Investigational Site	Moscow
Russian Federation	GSK Investigational Site	Moscow
Russian Federation	GSK Investigational Site	Moscow
Russian Federation	GSK Investigational Site	St. Petersburg
Russian Federation	GSK Investigational Site	St. Petersburg
Singapore	GSK Investigational Site	Singapore
Thailand	GSK Investigational Site	Bangkok
United Kingdom	GSK Investigational Site	Birmingham
United Kingdom	GSK Investigational Site	Chelmsford	Essex
United Kingdom	GSK Investigational Site	Glasgow
United Kingdom	GSK Investigational Site	Ipswich
United Kingdom	GSK Investigational Site	London
United Kingdom	GSK Investigational Site	London
United Kingdom	GSK Investigational Site	Manchester	Lancashire
United Kingdom	GSK Investigational Site	Nottingham
United Kingdom	GSK Investigational Site	Plymouth
United Kingdom	GSK Investigational Site	Sutton	Surrey
United States	GSK Investigational Site	Akron	Ohio
United States	GSK Investigational Site	Alhambra	California
United States	GSK Investigational Site	Bakersfield	California
United States	GSK Investigational Site	Bronx	New York
United States	GSK Investigational Site	Dallas	Texas
United States	GSK Investigational Site	Fullerton	California
United States	GSK Investigational Site	Henderson	Nevada
United States	GSK Investigational Site	Indianapolis	Indiana
United States	GSK Investigational Site	Jonesboro	Arkansas
United States	GSK Investigational Site	Long Beach	California
United States	GSK Investigational Site	Los Angeles	California
United States	GSK Investigational Site	Lubbock	Texas
United States	GSK Investigational Site	Metairie	Louisiana
United States	GSK Investigational Site	Northridge	California
United States	GSK Investigational Site	Oxnard	California
United States	GSK Investigational Site	Redondo Beach	California
United States	GSK Investigational Site	San Antonio	Texas
United States	GSK Investigational Site	Santa Barbara	California
United States	GSK Investigational Site	Santa Maria	California

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Countries where clinical trial is conducted

United States,  Canada,  France,  Hungary,  India,  Israel,  Korea, Republic of,  Malaysia,  Mexico,  Pakistan,  Peru,  Poland,  Russian Federation,  Singapore,  Thailand,  United Kingdom, 

References & Publications (1)

Johnston SR, Gómez H, Stemmer SM, Richie M, Durante M, Pandite L, Goodman V, Slamon D. A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer. Breast Cancer Res Treat. 2013 Feb;137(3):755-66. doi: 10.1007/s10549-012-2399-4. Epub 2013 Jan 3. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants With Progressive Disease at Week 12 in Cohort 1	The percentage of participants with progressive disease (PD) 12 weeks after randomization was measured. Per Response Evaluation Criteria In Solid Tumors (RECIST), a response of PD is defined as a >=20% increase in target lesions. Participants were also classified as having PD if their response at Week 12 was unknown or missing. Response was determined by an independent radiologist and by an investigator.	Week 12	No
Secondary	Overall Survival for Cohort 1	Overall survival (OS) is defined as the time from randomization until death due to any cause. Participants who are alive as of the date of last contact are censored. There was insufficient follow-up to adequately assess OS for Cohort 2. Median OS cannot be presented for the lapatinib arm because the upper bound of the 95% confidence interval is undefined due to insufficient follow-up.	Randomization until death due to any cause (up to 106.43 weeks)	No
Secondary	Response at Week 12 for Cohort 1 and Cohort 2	The percentage of participants achieving either a complete (CR) or partial (PR) tumor response per Response Evaluation Criteria in Solid Tumors (RECIST) is presented. CR, all detectable tumor has disappeared; PR, a >=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum; Progressive disease (PD), a >=20% increase in target lesions; Stable Disease, small changes that do not meet previously given criteria. IRC, independent review committee. Participants with an unknown or missing response were treated as non-responders.	Week 12	No
Secondary	Duration of Response in Cohort 1	Duration of response is defined as the length of time from the time from the first observation of response until progression of disease or death. Duration of response depends on two things: (1) when response is counted as starting; (2) when response is counted as ending.There were insufficient data to adequately assess duration of response for Cohort 2. IRC, independent review committee. For participants who do not progress or die, duration of response was censored at the date of last adequate assessment.	Time from first documented evidence of complete or partial response until the first documented sign of disease progression or death due to any cause (up to 106.71 weeks)	No
Secondary	Time to Response (Complete or Partial Response) in Cohort 1 and Cohort 2	Time to response is defined as the time from randomization to the time of first documented evidence of a complete (CR) or partial response (PR). The time to response will depend on when the response is counted as starting. Per RECIST: CR, all detectable tumor has disappeared; PR, a >=30% decrease in the sum of the target dimensions of the target lesions taking as a reference the baseline sum.	The time from randomization to the time of first documented evidence of complete or partial response (up to 81.14 weeks for Cohort 1 and 44.29 weeks for Cohort 2)	No
Secondary	Percentage of Participants With Progressive Disease at Week 12	The percentage of participants with progressive disease (PD) 12 weeks after randomization was measured. Participants were classified as having PD if their response at Week 12 was unknown or missing. Per Response Evaluation Criteria In Solid Tumors (RECIST), PD is defined as a >=20% increase in target lesions. IRC, independent review committee.	Week 12	No